Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 4/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 9/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30572166 | 1.00 | PTPRC (0.59) | PTPRCCTSLPTPN13PDK2KDM4E | |
| SCHEMBL30571717 | 0.92 | PTPRC (0.59) | PTPRCCTSLPTPN13PDK2KDM4E | |
| SCHEMBL26116640 | 0.92 | PTPRC (0.59) | PTPRCCTSLPTPN13PDK2KDM4E | |
| SCHEMBL26117162 | 0.86 | PDK2 (0.55) | PTPRCPDK2KDM4EMAPK1 | |
| SCHEMBL26112525 | 0.84 | PTPRC (0.59) | PTPRCCTSLPTPN13PDK2KDM4E | |
| SCHEMBL26116013 | 0.82 | PTPRC (0.51) | PTPRCCTSLPTPN13PDK2KDM4E | |
| SCHEMBL26581011 | 0.80 | PDK2 (0.54) | PTPRCCTSLPTPN13PDK2 | |
| SCHEMBL26120453 | 0.79 | PDK2 (0.56) | PTPRCPDK2 | |
| SCHEMBL26118039 | 0.79 | PTPRC (0.88) | PTPRCCTSLPTPN13KDM4EMAPT | |
| SCHEMBL30571795 | 0.79 | PTPRC (0.47) | PTPRCCTSLPTPN13PDK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | PTPRC 2222/4885CTSL 315/4885PTPN13 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.